Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target

PLoS ONE

Volumn 3, Issue 3, 2008, Pages

  Gallegos Ruiz, Mariëlle I ^a   Floor, Karijn ^a   Roepman, Paul ^b   Rodriguez, José A ^a   Meijer, Gerrit A ^a   Mooi, Wolter J ^a   Jassem, Ewa ^c   Niklinski, Jacek ^d   Muley, Thomas ^e   van Zandwijk, Nico ^f   Smit, Egbert F ^a   Beebe, Kristin ^g   Neckers, Len ^g   Yistra, Bauke ^a   Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Agendia NV   (Netherlands)

^c UNIVERSITY OF GDA SK   (Poland)

^d UNIVERSITY OF BIALYSTOK   (Poland)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; TANESPIMYCIN; MESSENGER RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 14Q; CHROMOSOME DELETION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; RNA ISOLATION; VALIDATION PROCESS; ADENOCARCINOMA; CELL CULTURE; CHROMOSOME 14; CHROMOSOME ABERRATION; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; GENOME; LARGE CELL CARCINOMA; LUNG TUMOR; METABOLISM; METASTASIS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 14; FEMALE; FOLLOW-UP STUDIES; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 45849105629     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001722     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Murray T, Xu JQ, et al. (2006) Cancer statistics, 2006. Ca-A Cancer Journal for Clinicians 56: 106-130.
2. Sekido Y, Fong KM, Minna JD (2003) Molecular genetics of lung cancer. Annual Review of Medicine-Selected Topics in the Clinical Sciences 54: 73-87.
3. Balsara BR, Testa JR (2002) Chromosomal imbalances in human lung cancer. Oncogene 21: 6877-6883.
4. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, et al. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541.
5. van de Wiel MA, Kim KI, Vosse SJ, van Wieringen WN, Wilting SM, et al. (2007) CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 23: 892-894.
6. van Wieringen WN, Belien JAM, Vosse SJ, Achame EM, et al. (2006) ACE-it: a tool for genome-wide integration of gene dosage and RNA expression data. Bioinformatics 22: 1919-1920.
7. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
8. Lu Y, Lemon W, Liu PY, Yi YJ, Morrison C, et al. (2006) A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. Plos Medicine 3: 2229-2243.
9. van den IJssel P, Tijssen M, Chin SF, Ejk P, Carvalho B, et al. (2005) Human and mouse oligonucleotide-based array CGH. Nucleic Acids Research 33.
10. Glas AM, Floore A, Delahaye LJMJ, Witteveen AT, Pover RCF, et al. (2006) Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7.
11. van de Wiel MA, Kim KI, Vosse SJ, van Wieringen WN, Wilting SM, et al. (2007) CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 23: 892-894.
12. Berjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate-A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 57: 289-300.
13. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, et al. (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Research 30: e57.
14. Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemotherapy and Pharmacology 42: 273-279.
15. Shibata T, Uryu S, Kokubu A, Hosoda F, Ohki M, et al. (2005) Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: Its association with clinicopathologic features. Clinical Cancer Research 11: 6177-6185.
16. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, et al. (2005) High-resolution genomic profiles of human lung cancer. Proceedings of the National Academy of Sciences of the United States of America 102: 9625-9630.
17. Beer DG, Kardia SLR, Huang CC, Giordano TJ, Levin AM, et al. (2002) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nature Medicine 8: 816-824.
18. Wigle DA, Jurisica I, Radulovich N, Pintilie M, Rossant J, et al. (2002) Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Research 62: 3005-3008.
19. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, et al. (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. New England Journal of Medicine 356: 11-20.
20. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine 350: 2129-2139.
21. Pao W, Wang TY, Riely GJ, Miller VA, Pan QL, et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. Plos Medicine 2: 57-61.
22. Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Seminars in Ontology 28: 13-19.
23. Balsara BR, Sonoda G, duManoir S, Siegfried JM, Gabrielson E, et al. (1997) Comparative genomic hybridization analysis detects frequent, often high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas. Cancer Research 57: 2116-2120.
24. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, et al. (2002) Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program or human breast tumors. Proceedings of the National Academy of Sciences of the United States of America 99: 12963-12968.
25. Redon R, Muller D, Caulee K, Wanherdrick K, Abecassis J, et al. (2001) A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Research 61: 4122-4129.
26. Tay ST, Leong SH, Yu K, Aggarwal A, Tan SY, et al. (2003) A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Research 63: 3309-3316.
27. Choi JS, Zheng LT, Ha E, Lim YJ, Kim YH, et al. (2006) Comparative genomic hybridization array analysis and real-time PCR reveals genomic copy number alteration for lung adenocarcinomas. Lung 184: 355-362.
28. Burrows F, Zhang H, Kamal A (2004) Hsp90 activation and cell cycle regulation. Cell Cycle 3: 1530-1536.
29. Yang SC, Qu S, Perez-Tores M, Sawai A, Rosen N, et al. (2006) Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Research 66: 6990-6997.
30. Shimamura T, Lowell AM, Engelman JA, Shapiro GI (2005) Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Research 65: 6401-6408.
31. Cullman SB, Whitesell L (2006) Heat shock protein 90: A unique chemotherapeutic target. Seminars in Oncology 33: 457-465.
32. Zhang H, Burrows F (2004) Targeting multiple signal transduction pathways through inhibition of Hsp90. Journal of Molecular Medicine-Jmm 82: 488-499.
33. Thomas CY, Stallings-Mann M, Zang H, Yang YC, Burrows F, et al. (2003) Glioblastoma (GBM) cells that overexpress epidermal growth factor receptors (EGFR) are sensitive to HSP90 but not EGFR kinase inhibitors. Clinical Cancer Research 9: 6098S.
34. Braga-Basaria M, Hardy E, Gottfried R, Burman KD, Saji M, et al. (2004) 17-allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels. Journal of Clinical Endocrinology and Metabolism 89: 2982-2988.
35. Yang J, Yang JM, Iannone M, Shih WJ, Lin Y, et al. (2001) Disruption of the EF-2 kinase/Hsp90 protein complex: A possible mechanism to inhibit glioblastoma by geldanamycin. Cancer Research 61: 4010-4016.
36. Zsebik B, Citri A, Isola J, Yarden Y, Szollosi J, et al. (2006) Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunology Letters 104: 146-155.
37. Xu WP, Neckers L (2007) Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cell. Clinical Cancer Research 13: 1625-1629.